Prostate Cancer’s Risk and Mortality Dropping or Stabilizing
Prostate cancer’s incidence and deadliness has declined or stabilized in much of the world in recent years, with the greatest decrease in risk evident in the U.S., a study reports. Read full article here.
Patient Survey on Impact of Prostate Cancer
Men who are diagnosed with prostate cancer at later stages of the disease are more likely to say that their disease has affected several aspects of their life, including their self-esteem, how they share feelings with others, and how they feel about their sexual...
Bucking Landmark U.S. Recommendation, Oncologist Urges PSA Screening
Despite a United State Preventative Service Task Force 2012 conclusion that routine tests for prostate cancer are unnecessary, a prominent oncologist believes such screenings should be encouraged. Click HERE to read the full article.
Prostate Cancer Scoring Method May Not Accurately Predict Outcomes in Black Men
Black men diagnosed with prostate cancer are 2 times more likely to actually have a more aggressive, fatal form of the disease than those of other races, suggesting that the current prostate cancer score method may be underestimating the risk of death among black...
Top Ten Steps to Fight Prostate Cancer
If you have been diagnosed with prostate cancer, these steps will help you understand what to do next.
10-Year Survival of Young Low- and Intermediate-risk Prostate Cancer Patients Better with Radiation than Surgery
Radiation Therapy approaches — including brachytherapy and external beam radiation therapy (EBRT) — lead to better 10-year survival rates than prostate surgery in young patients with low- and intermediate-risk prostate cancer, a study shows. The research,...
Prostate Cancer Free Foundation Study Update
The Prostate Cancer Free Foundation has published an updated version of the comparative analysis study. The update represents the treatment outcomes of over 119,000 men. Click here for the update:
PSA TESTING CUTS DEATHS, Shows Value of Long Term Screening
The longest screening study on prostate cancer shows blood test measuring the levels of PSA, a well-known marker of prostate cancer, cuts deaths from the disease by nearly 30%. The study followed 20,000 men in Sweden for more than two decades and was featured...
Study Shows Radiation Treatments Delay Metastasis, Recurrence in Aggressive Prostate Cancers
A recent study shows that patients with aggressive forms of prostate cancer, who undergo radiation therapy- including external beam radiation therapy and brachytherapy- experience longer periods of time before metastasis or cancer...
Support the Foundation while you shop for the holidays
Black Friday and Cyber Monday are two of the busiest shopping days of the year. Support us when you shop on Amazon on Black Friday, Cyber Monday and the holiday season. Begin your Amazon shopping on this link: smile.amazon.com/ch/27-4434212 and Amazon donates to the...
75% of men with slow-growing prostate cancer fail to get appropriate follow-up
A recent study out of Australia found that nearly 3 out of 4 men with slow-growing prostate cancer, that chose to pursue active surveillance, are not receiving the appropriate follow-up to monitor the disease. These men are not getting the follow-up they need, and in...
3 in 4 Americans are Unaware Prostate Cancer Doesn’t Have Early Symptoms
When it comes to Prostate Cancer awareness, we have a ways to go here in the US. Recent study found that nearly 3 out of 4 Americans are unaware that early-stage prostate cancer has a lack of noticeable symptoms, and less than one-third know that men could receive...
Prostate Cancer Diagnosis – Do You Really Know “All” Your Treatment Options?
A Prostate Cancer diagnosis can be devastating and understanding the available treatment options can be overwhelming and is often more perplexing and confusing than the diagnosis itself. Leading to the confusion, there are many treatment options for prostate cancer,...
Early diagnosis is key to surviving prostate cancer
Dr. Gregory Merrick says the key to surviving prostate cancer is to undergo screening for early prostate cancer detection. That combined with a healthy lifestyle is key to men's health. You can read his whole interview here: "Early Diagnosis Remains Key to Surviving...
September is Prostate Cancer Awareness Month!
September is National Prostate Cancer Awareness Month. Did you know that one in six men will be diagnosed with prostate cancer during their lifetime. It's important to talk to your family and friends about the risk of prostate cancer, and the importance of screening....
Finland study finds how genetic mutation can cause aggressive forms of prostate cancer
Researchers at the University of Oulu in Finland, have found that a type of mutation in a single nucleotide plays a role in the development of aggressive prostate cancer. The study identified several key risk factors involved, and genetic predisposition was one of the...
Study finds nearly 3 out of 4 men on active surveillance are failing to get appropriate follow-up
The second most common cancer in men worldwide (after skin cancer) is still prostate cancer. Most cases diagnosed are slow growing, and may not require immediate treatment. Therefore, a lot of patients pursue active surveillance. According to a recent study in...
Check out the latest video from PCaFree Foundation
Click here to view our latest video featuring Dr. Alex Hsi.
More and more men with low-risk prostate cancer are pursuing active surveillance over aggressive treatment.
More American men with low-risk prostate cancer are being persuaded by their doctor to reject immediate surgery and/or radiation in favor of active surveillance. This move is sparing men’s sexual health without increasing their risk of death. A study done by the VA...
New Prostate Cancer Prognostic Test Soon-To-Be Available
A new prostate cancer prognostic test is in the works and soon-to-be available worldwide. MDxHealth recently signed an agreement that gives it licensing rights to market and manufacture the test. The test, InformMDx, looks at the recently validated biomarker PDE4D7,...
Prostate Cancer isn’t Just a “Man’s Disease”
It’s a simple fact anatomical fact that women will never have to worry about receiving their own prostate cancer diagnosis. Prostate cancer has long been referred to as a “man’s disease,” one must not overlook the burden that is shared by the patient’s partner. A...
PCa Commentary
Expert Commentary On The Latest Prostate Cancer Topics
Written by Dr. Ed Weber
PCa Commentary is a well-researched, clearly presented commentary targeted to medical providers and others interested in current prostate cancer treatment. Each PCa Commentary edition offers an analysis of new developments in the field of prostate cancer with essays discussing and evaluating treatment management options for this disease.
PCa Commentary #135 Managing PCa Recurrence Following Radiation Therapy
Managing PSA Recurrence Following Primary Radiation Therapy: Evolving Regimens for Focal Treatment Biochemical recurrence following primary irradiation is relatively common. “A recent series of 2694 patients treated with doses above 78 Gy revealed 10-year...
PCa Commentary #134 Radioligand Therapy – The “VISION” Protocol: A treatment opportunity for men with late-stage metastatic castration-resistant prostate cancer.
Radioligand therapy (RLT) - i.e. PSMA directed endoradiation with Lutetium-177 - has been developed to the extent that it is a realistic option for men with late stage, heavily pretreated metastatic castration-resistant prostate cancer. The national protocol...
PCa Commentary #133 GENOMIC SEQUENCING FOR PROSTATE CANCER – Which Men Gain a Clinical Benefit from Genomic Testing.
The commonly cited goal of ‘personalized medicine’ in regards to treatment selection based on genomic testing is early in the ‘work in progress’ stage. Breathtaking advances in next generation sequencing are very promising, but currently there are only limited options...
PCa Commentary #132 Resistance to Therapeutic Agents Targeting the Androgen Receptor and Insights into Sequencing Treatments for Optimal Outcomes
Ever since the first orchiectomy for metastatic prostate cancer in 1941 researchers and clinicians have been determinedly trying to restrain the androgen receptor (AR) by manipulating its hormone environment. But this wily adversary, like Houdini, after initial...
PCa Commentary #131: ENZALUTAMIDE (‘XTANDI’): AN UPDATE — The Many Faces of Enzalutamide
Enzalutamide (ENZ) was reviewed in the PCa Commentary of March/April 2014. Many important developments have taken place since then. This Commentary will discuss the current indications for ENZ and new studies of ENZ as monotherapy. A subsequent Commentary will address...
PCa Commentary #130: Ga68-PSMA-11 PET/CT Scanning at Initial Diagnosis for High-Risk Prostate Cancer: What is missed by conventional staging and does it matter.
This Commentary benefitted from a review and suggestions from Thomas Hope, MD, Associate Professor of Abdominal Imaging and Nuclear Medicine, UCSF THE FIRST QUESTION likely, is why present a Commentary about the Gallium68-PSMA-11 PET/CT scan. Its...
PCa Commentary: #129 THE AXUMIN PET/CT SCAN: ITS CLINICAL UTILITY — AN UPDATE
It has been one year since the Commentary featured the Axumin PET/CT in the November 2017 issue [control+click link to follow]. A great deal of new research about this scan performance has been published since then. The material in this issue is based on this...
PCa Commentary #128: IMMUNOTHERAPY FOR PROSTATE CANCER: Immune Checkpoint Inhibitors — The Search for Clues for Which Men Will Benefit and How Best to Treat Them.
Harnessing our immune system to treat cancer has been an elusive goal for decades. Research in immunotherapy is intense with active study of the newest advances, i.e. checkpoint inhibitors and CAR T cell technology. Checkpoint inhibitors have yielded encouraging...
PCa Commentary #127: DECIPHER AND A HYBRID CLINICAL – GENOMIC CLASSIFIER: Improving the Prognostic Accuracy of NCCN Risk Categories
The conventional National Cooperative Cancer Network (NCCN) risk categories — low-, intermediate-, and high-risk are largely based on the Gleason score as determined by the microscopic appearance of cells and their organization. However, beneath the surface appearance...
PCa Commentary #126: ESTROGEN — OUR SISTER HORMONE: Addressing the Dark Side of Androgen Deprivation Therapy (ADT)
Many of the important adverse effects associated with androgen suppression with Lupron, Firmagon, or orchiectomy result from estrogen deficiency. Estimates vary, but 50%, 75%, or as much as 80% of a man’s serum estrogen arises from enzymatic conversion of serum...
UNDERSTAND PROSTATE CANCER.
What is Prostate Cancer?
What is Prostate Cancer, the Symptoms, Risk Factors? What does the Prostate do, where is it located?
Diagnosed with Prostate Cancer?
What tests confirm the presence of prostate cancer? Learn how doctors diagnose prostate cancer.
Treating Prostate Cancer.
Patients have options when it comes to the prostate cancer treatments. Learn about your options.
Prostate Cancer Surgery or Radiation ???
Need Treatment? YOU NEED THIS STUDY! This fifteen year study compares treatment success rates, following 119,000+ patients treated for prostate cancer, to see who became Prostate Cancer Free. Treated once. No more treatment. No recurrence. Get your copy of the study to discuss with your family and Doctor.
Help other men make better treatment decisions.
A $25 donation today enables the Foundation to continue the work of educating men and their loved ones about prostate cancer.. Prostate Cancer Free is a 501(c)(3) non-profit, so your donation is tax deductible. Please Donate!